14278-49-0

Usage

InChI:InChI=1/C9H21N3O/c1-9(13)12-8-4-7-11-6-3-2-5-10/h11H,2-8,10H2,1H3,(H,12,13)

Upstream product

• 85681-31-8 1-[3-(4-Amino-butyl)-tetrahydro-pyrimidin-1-yl]-ethanone 
• 73453-98-2 1-(4-aminobutyl)-1,2,3,4,5,6-hexahydropyrimidine 
• 14464-29-0 N-acetoxysuccinimide 
• 124-20-9 N-(3-aminopropyl)-1,4-diaminobutane 
• 85681-30-7 Toluene-4-sulfonic acid; compound with 4-(tetrahydro-pyrimidin-1-yl)-butylamine 
• 126993-29-1 {4-[(3-Acetylamino-propyl)-tert-butoxycarbonyl-amino]-butyl}-carbamic acid tert-butyl ester 

Downstream Products

• 109-76-2 Trimethylenediamine 
• 82414-35-5 N¹,N³-spermidinebis(acetamide) 

Relevant academic research and scientific papers

Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N-Acetyltransferase NAT2

N-Acetyltransferases play critical roles in the deactivation and clearance of xenobiotics, including clinical drugs. NAT2 has been classified as an arylamine N-acetyltransferase that mainly converts aromatic amines, hydroxylamines, and hydrazines. Herein, we demonstrate that the human arylamine N-acetyltransferase NAT2 also acetylates aliphatic endogenous amines. Metabolomic analysis and chemical synthesis revealed increased intracellular concentrations of mono- and diacetylated spermidine in human cell lines expressing the rapid compared to the slow acetylator NAT2 phenotype. The regioselective N8-acetylation of monoacetylated spermidine by NAT2 answers the long-standing question of the source of diacetylspermidine. We also identified selective acetylation of structurally diverse alkylamine-containing drugs by NAT2, which may contribute to variations in patient responses. The results demonstrate a previously unknown functionality and potential regulatory role for NAT2, and we suggest that this enzyme should be considered for re-classification.

Human spermidine/spermine N1-acetyltransferase

The present invention provides a human spermidine/spermine N1-acetyltransferase (S-ACTR) and polynucleotides which identify and encode S-ACTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding S-ACTR and a method for producing S-ACTR. The invention also provides for use of S-ACTR and agonists, antibodies, or antagonists specifically binding S-ACTR, in the prevention and treatment of cancers. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding S-ACTR for the treatment of diseases associated with the expression of S-ACTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, or antibodies specifically binding S-ACTR.

Facile synthesis of monoacetylated spermidines, illustrating selective deacetylation and application of a common precursor.

The synthesis of all three monoacetylated spermidines is reported. N4-Acetylspermidine was obtained in four steps from spermidine via the triacetylated intermediate by selective deacetylation after exhaustive t-butoxycarbonylation as well as directly from